{"id":"NCT02025725","sponsor":"Evoke Pharma","briefTitle":"Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis","officialTitle":"Phase 3 Study of Intranasal Metoclopramide in Women With Symptomatic Diabetic Gastroparesis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03-27","primaryCompletion":"2016-05-27","completion":"2016-06-27","firstPosted":"2014-01-01","resultsPosted":"2020-02-11","lastUpdate":"2020-07-07"},"enrollment":205,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Gastroparesis"],"interventions":[{"type":"DRUG","name":"Metoclopramide Nasal Spray","otherNames":["EVK-001"]},{"type":"DRUG","name":"Placebo Nasal Spray","otherNames":["EVK-001 Placebo"]}],"arms":[{"label":"10 mg Metoclopramide Nasal Spray","type":"EXPERIMENTAL"},{"label":"Placebo Nasal Spray","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is provide confirmation of the safety and efficacy of Metoclopramide Nasal Spray compared to placebo in reducing the symptoms of diabetic gastroparesis in adult women.","primaryOutcome":{"measure":"Gastroparesis Symptom Assessment (GSA), a Patient Reported Outcome Measure","timeFrame":"Baseline Period to Week 4 of the Treatment Period","effectByArm":[{"arm":"10 mg Metoclopramide Nasal Spray","deltaMin":-0.925,"sd":0.935},{"arm":"Placebo Nasal Spray","deltaMin":-0.896,"sd":0.947}],"pValues":[{"comp":"OG000 vs OG001","p":"0.881"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":10},"locations":{"siteCount":50,"countries":["United States"]},"refs":{"pmids":["37924856"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":102},"commonTop":["Headache","Abdominal pain","Cough","Nasal discomfort","Abdominal tenderness"]}}